Literature DB >> 19170049

Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

I-Tien Yeh1, Robert L Reddick, Addanki Pratap Kumar.   

Abstract

BACKGROUND: Transgenic adenocarcinoma of mouse prostate (TRAMP) mice, derived by prostate specific expression of SV40 large T antigen using the rat probasin promoter, all develop prostate tumors akin to human prostate cancers. More recently, epithelial-stromal (ES) tumors resembling phyllodes tumors have been described in the seminal vesicles of TRAMP mice. We report malignancy arising in these ES tumors of the seminal vesicles in TRAMP mice.
METHODS: H&E stained sections from 28-week-old TRAMP mice autopsies were examined. Immunostains (cytokeratin, vimentin, desmin, and MIB-1) and electron microscopy were performed on selected blocks of the genitourinary system and metastatic tumor nodules.
RESULTS: The seminal vesicles frequently develop tumors containing broad papillae, with bland epithelium and a cellular spindled stroma just beneath the epithelium. The stromal cells have high nuclear to cytoplasmic ratio, frequent apoptotic cells and mitoses. In some cases, the stromal cells become large mass lesions that overgrow the prostate. The epithelium can also proliferate and become malignant. The tumors have high proliferation indices by MIB-1. Some metastatic tumors have characteristics similar to the seminal vesicle ES tumor.
CONCLUSIONS: Metastatic tumors in TRAMP mice show three patterns: (1) A definite adenocarcinoma pattern metastatic from the prostate; (2) poorly differentiated tumor without epithelial differentiation; (3) carcinosarcomatous pattern. The carcinosarcomatous pattern and some of the poorly differentiated tumors likely arise from seminal vesicle ES tumors. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19170049     DOI: 10.1002/pros.20924

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse.

Authors:  Erin M Goodwin; Qing Zhong; Catherine S Abendroth; Lindsay K Ward-Kavanagh; Todd D Schell; Timothy K Cooper
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

2.  ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.

Authors:  Jody T Mack; Kristi L Helke; Gabrielle Normand; CoDanielle Green; Danyelle M Townsend; Kenneth D Tew
Journal:  Cancer Lett       Date:  2010-10-30       Impact factor: 8.679

Review 3.  Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: the best and the worst.

Authors:  Sari Jäämaa; Marikki Laiho
Journal:  Mol Oncol       Date:  2012-06-18       Impact factor: 6.603

Review 4.  Serially heterotransplanted human prostate tumours as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  J Cell Mol Med       Date:  2009-10-29       Impact factor: 5.310

5.  A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.

Authors:  Kendra A Williams; Minnkyong Lee; Ying Hu; Jonathan Andreas; Shashank J Patel; Suiyuan Zhang; Peter Chines; Abdel Elkahloun; Settara Chandrasekharappa; J Silvio Gutkind; Alfredo A Molinolo; Nigel P S Crawford
Journal:  PLoS Genet       Date:  2014-11-20       Impact factor: 5.917

6.  P21 and P27 promote tumorigenesis and progression via cell cycle acceleration in seminal vesicles of TRAMP mice.

Authors:  Tonghui Li; Fangfang Wang; Yanmei Dang; Jiajie Dong; Yu Zhang; Chi Zhang; Ping Liu; Yanhong Gao; Xiaojun Wang; Sijun Yang; Shan Lu
Journal:  Int J Biol Sci       Date:  2019-08-19       Impact factor: 6.580

7.  Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses.

Authors:  Elena Jachetti; Stefania Mazzoleni; Matteo Grioni; Alessia Ricupito; Chiara Brambillasca; Luca Generoso; Arianna Calcinotto; Massimo Freschi; Anna Mondino; Rossella Galli; Matteo Bellone
Journal:  Oncoimmunology       Date:  2013-04-16       Impact factor: 8.110

Review 8.  Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition.

Authors:  Ingrid Espinoza; Radhika Pochampally; Fei Xing; Kounosuke Watabe; Lucio Miele
Journal:  Onco Targets Ther       Date:  2013-09-06       Impact factor: 4.147

9.  Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Authors:  D C Mansfield; J N Kyula; N Rosenfelder; J Chao-Chu; G Kramer-Marek; A A Khan; V Roulstone; M McLaughlin; A A Melcher; R G Vile; H S Pandha; V Khoo; K J Harrington
Journal:  Gene Ther       Date:  2016-01-27       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.